Design, Molecular Docking, and Molecular Dynamics Simulation of Cyclohexanone Curcumin Derivatives as Anti-Breast Cancer Agents

Human epidermal growth factor receptor-2 (HER2) is a critical therapeutic target in oncology, yet developing effective inhibitors remains a priority. While curcumin derivatives have emerged as potential anticancer agents, their specific molecular interactions with HER2 require further elucidation. This study investigated the inhibitory potential of twelve curcumin derivatives against HER2 using an integrated in silico strategy that comprised molecular docking, 100 ns molecular dynamics (MD) simulations, Molecular Mechanics Poisson-Boltzmann Surface Area (MM-PBSA) free energy calculations, and Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) profiling. Docking analyses revealed that compounds I (2,6-bis((E)-4-methoxy-3-nitrobenzylidene)cyclohexan-1-one), K (2,6-bis((E)-4-chloro-3-nitrobenzylidene) cyclohexan-1-one), A (2,6-bis((E)-3-hydroxy-4-methoxybenzylidene)cyclohexan-1-one), and C (2,6-bis((E)-4-chloro-3-hydroxybenzylidene)cyclohexan-1-one) exhibited significantly stronger binding affinities (−11.04 to −10.05 kcal/mol) than the native ligand 03Q (−8.89 kcal/mol), forming stable interactions with key active-site residues, particularly Met801. MD simulations and MM-PBSA calculations validated the conformational stability of these complexes, with Compound I demonstrating the most favorable binding free energy (−45.39 kcal/mol). Although all derivatives complied with Lipinski’s Rule of Five, ADMET predictions highlighted distinct safety profiles. Compounds A and C displayed superior pharmacokinetics, high intestinal absorption, and no mutagenicity or hepatotoxicity. Conversely, the high-affinity compounds I and K exhibited potential toxicity liabilities despite their dynamic stability. Collectively, these findings identify Compound A as the most promising lead candidate for HER2-targeted drug development, while the potent scaffold of Compound I warrants structural optimization to improve its safety profile.

Authors

Institutions

Publication Details

Journal
Tropical Journal of Natural Product Research
Published
2026-05-01
DOI
https://doi.org/10.26538/tjnpr/v10i4.64
Primary Topic
Curcumin's Biomedical Applications
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Design, Molecular Docking, and Molecular Dynamics Simulation of Cyclohexanone Curcumin Derivatives as Anti-Breast Cancer Agents

Faris Hermawan, Anita D. Puspitasari, Ibrahim Arifin, Rissa L. Vifta et al.
Tropical Journal of Natural Product Research
Curcumin's Biomedical Applications
article

Design, Molecular Docking, and Molecular Dynamics Simulation of Cyclohexanone Curcumin Derivatives as Anti-Breast Cancer Agents

Faris Hermawan, Anita D. Puspitasari, Ibrahim Arifin, Rissa L. Vifta, Yudhi D. Kurniawan, Puspa D.N. Lotulung, Maria Ulfah
article en

Abstract

Human epidermal growth factor receptor-2 (HER2) is a critical therapeutic target in oncology, yet developing effective inhibitors remains a priority. While curcumin derivatives have emerged as potential anticancer agents, their specific molecular interactions with HER2 require further elucidation. This study investigated the inhibitory potential of twelve curcumin derivatives against HER2 using an integrated in silico strategy that comprised molecular docking, 100 ns molecular dynamics (MD) simulations, Molecular Mechanics Poisson-Boltzmann Surface Area (MM-PBSA) free energy calculations, and Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) profiling. Docking analyses revealed that compounds I (2,6-bis((E)-4-methoxy-3-nitrobenzylidene)cyclohexan-1-one), K (2,6-bis((E)-4-chloro-3-nitrobenzylidene) cyclohexan-1-one), A (2,6-bis((E)-3-hydroxy-4-methoxybenzylidene)cyclohexan-1-one), and C (2,6-bis((E)-4-chloro-3-hydroxybenzylidene)cyclohexan-1-one) exhibited significantly stronger binding affinities (−11.04 to −10.05 kcal/mol) than the native ligand 03Q (−8.89 kcal/mol), forming stable interactions with key active-site residues, particularly Met801. MD simulations and MM-PBSA calculations validated the conformational stability of these complexes, with Compound I demonstrating the most favorable binding free energy (−45.39 kcal/mol). Although all derivatives complied with Lipinski’s Rule of Five, ADMET predictions highlighted distinct safety profiles. Compounds A and C displayed superior pharmacokinetics, high intestinal absorption, and no mutagenicity or hepatotoxicity. Conversely, the high-affinity compounds I and K exhibited potential toxicity liabilities despite their dynamic stability. Collectively, these findings identify Compound A as the most promising lead candidate for HER2-targeted drug development, while the potent scaffold of Compound I warrants structural optimization to improve its safety profile.

Tropical Journal of Natural Product Research
Sultan Agung Islamic University (ID), Universitas Wahid Hasyim (ID), National Nuclear Energy Agency of Indonesia (ID)
Openalex Percentile: Top 10%
Curcumin's Biomedical Applications
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.